Loss of p65 accelerates the myogenic program in MEFs. (A) p65+/+ and p65−/− MEFs were infected with MSCV-MyoD and, after puromycin selection, were sorted for GFP to ensure equal MyoD levels. Cells were then probed for p65 and MyoD (45 kD) protein. α-Tubulin (55 kD) was used as a loading control. (B) p65+/+ and p65−/− MEFs stably expressing MyoD were differentiated, and lysates were then probed for the indicated myogenic differentiation markers. (C) Cells were differentiated as in B, and MyHC immunofluorescence was performed. (D) p65−/− MEFs were transfected with TnI-luc and either vector plasmid, wild-type p65 (1–551), or p65 TA mutants (1–521 and 1–313) along with MyoD. Cells were then differentiated, and lysates were prepared for luciferase assays. RLU, relative light units. (E) p65−/− MEFs were reconstituted with either vector and full-length or truncated p65 along with MSCV-MyoD. After selection, whole cell lysates were prepared and probed for p65, MyoD, and α-tubulin. (F) Cells were infected as in E, differentiated for 72 h, fixed, and stained for MyHC. (G) p65−/− MEFs were transfected with MyoD, TnI-luc, and either vector control, wild-type p65 (WT), or p65 constructs containing S/A mutation at positions 276, 529, and 536. MEFs were differentiated and harvested after 48 h for luciferase assays. (H) Relative luciferase activities from p65−/− MEFs transfected with MyoD, TnI-luc, and either vector control, wild-type p65, or p65 (1–313) containing the S276A mutation. Error bars represent SEM. Bars: (C) 200 μm; (F) 80 μm.